Our reporter Cao Weixin
After taking the concept of "New Crown Oral Drugs", the stock price of Jingxing Pharmaceutical, a veteran traditional Chinese medicine stock, returned to more than 10 yuan after more than three years.
According to the statistics of Oriental Fortune Choice, from December 24, 2021 to January 5, 2022, Essence Pharmaceuticals closed at the limit-up price for 8 consecutive trading days, with a cumulative increase of 114.62%.
During the period, the company's share price hit a new high in the past three years, reaching a maximum of 13.65 yuan per share.
However, the good times did not last long. After pulling 8 daily daily limits, the share price of Essence Pharmaceuticals has plummeted in the past two trading days.
As of the close on January 7, the company's stock price closed at 11.22 yuan per share, down 17.8% in two trading days.
The stock price has experienced a roller coaster ride. What is the gold content of Essence Pharmaceuticals as a concept stock of "New Crown Oral Drugs"?
A reporter from Securities Daily called Essence Pharmaceuticals to inquire about ritonavir series intermediates. The relevant staff of the company's securities department replied to the reporter, "The company's stock price has fluctuated a lot recently. If you need to know the situation of the subsidiary, ask Senxuan Pharmaceuticals. It’s more appropriate.” Subsequently, the staff member declined the interview request on the grounds that the secretary of the board of directors was on a business trip.
4 times on the Dragon Tiger list in half a month
According to the public information of the Shenzhen Stock Exchange, on December 27, 2021, December 30, 2021, and January 5, 2022, Essence Pharma’s price increase deviation value during the abnormal period reached 21.21%, 29.07%, and 21.84%. Tiger list.
On January 7, the company was listed again due to the deviation of the daily price drop of 8.85%.
The well-known "Lhasa Corps" sales department in the market appeared to buy and sell seats.
"The new crown oral drug is still only in the concept stage. It has not completed clinical verification, and it is still a long way from the official launch. Then, when there is only a concept, the stock price doubles in a short period of time, indicating that hot money is over-hyping the concept. Hot money It is also to use this concept to fight for income." Shen Meng, executive director of Chanson Capital, said in an interview with a reporter from "Securities Daily".
Why did the hot money speculate on this old-fashioned Chinese medicine stock?
This stems from the fact that on December 22, 2021, Pfizer's "Paxlovid" was approved by the FDA, becoming the first oral drug for the new crown in the United States.
Influenced by Pfizer's special drugs, pharmaceutical intermediates have become a hotly sought after concept in the market.
The reporter inquired about the announcement and learned that Jiangsu Senxuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Senxuan Pharmaceutical"), a holding subsidiary of Essence Pharmaceuticals, does produce and sell ritonavir series of pharmaceutical intermediates.
In 2021, Senxuan Pharmaceutical's ritonavir pharmaceutical intermediates are expected to achieve a sales volume of 11 tons and a sales revenue of 16.84 million yuan, which is expected to decrease by about 33% and 32% year-on-year respectively.
Similar to many pharmaceutical companies, after the concept of "new crown oral medicine", the share price of Essence Pharmaceuticals began to take off.
After pulling the daily limit for 5 consecutive times, the company's share price broke through 10 yuan.
On the evening of January 3rd, Essence Pharma disclosed the company's director and general manager Zhou Yunzhong's "Reduction Plan". Zhou Yunzhong plans to conduct centralized bidding through the stock exchange 15 trading days from the date of the announcement to July 25, 2022 The total reduction of the company's shares in the transaction method does not exceed 966,000 shares.
However, the performance of the company's stock price has not been affected by the executives' shareholding reduction plan, and it has continued to advance all the way.
On January 4 and January 5, the company's stock price rose by the limit for two consecutive days.
Share price change companies take the initiative to "cool down"
The reporter found on the investor interaction platform that in the past two weeks, many investors have left messages asking about the ritonavir intermediates of Essence Pharmaceuticals and Pfizer's oral drugs for the treatment of new crowns.
In its initial response, Essence Pharma did not provide a direct response to whether the company has a related partnership with Pfizer.
After repeated inquiries from investors, the company's response has become more detailed and affirmative.
On January 4, the 2019 semi-annual report of the subsidiary Jiangsu Senxuan proposed by the investor clearly stated that it provides high-quality products for Gilead in the United States and is an important customer of the company. Has the subsidiary provided ritonavir for Gilead in the United States? Intermediate products?", the company replied, "The company's subsidiary Senxuan Pharmaceutical currently has no direct supply cooperation with Gilead." On January 5, the company replied again to a similar question, "In 2019, the company Subsidiary Senxuan Pharmaceuticals does cooperate with Gilead, and currently there is no cooperative supply."
From the point of view of time, the company's stock price plummeted just after the company clearly replied to investors on January 5 that "Senxuan Medicine and Gilead have no cooperation in supply".
On January 6, the company's stock price opened at the limit-down price of 12.29 yuan per share, down 8.64% throughout the day.
The next trading day, the company's stock price fell again.
"The information disclosure of listed companies cannot be passively conducted through the investor interaction platform, but should be more proactive in clarifying some rumors through announcements in a timely manner, otherwise it will not rule out the possibility of intentional or unintentional laissez-faire speculation." Shen Meng said.
Wang Zhibin, a lawyer from Shanghai Minglun Law Firm, said, "When the stock price changes, the company is obliged to promptly and clearly disclose the complete relationship between its business and the 'hot spots', which should be done in one step and clearly explained, rather than limited to interactive transactions. Reply to specific questions on the platform. Even if the questions asked by investors are limited to one aspect, the company should still reply to the more critical questions that investors did not ask.”
"The announcement of Essence Pharmaceuticals on January 5 is relatively complete in content. If the company can reply completely on the interactive platform as soon as possible, there may not be a sharp fluctuation in the stock price." Wang Zhibin added.
(Securities Daily)